US · Healthcare · Biotechnology
EPS came in at -1.28 against a street estimate of -1.17 — a miss of 9.4%.
Analysts rate Beam Therapeutics Inc a strong buy (13 buy, 2 hold, 0 sell out of 15) with an average price target of $49.38.
| Fund | Stake |
|---|---|
| FMR Inc | 12.21% |
| Farallon Capital Management, L.L.C. | 9.91% |
| ARK Investment Management LLC | 9.91% |
| BlackRock Inc | 8.71% |
| State Street Corp | 5.64% |
| Vanguard Portfolio Management, LLC | 4.76% |
| Vanguard Capital Management, LLC | 4.45% |
| ARCH VENTURE CORP | 4.40% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 license and collaboration revenue was $307,000, down from $9.698 million in the third quarter of 2025. • Nine- | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net loss was $134.4 million, or $1.28 per share, compared with a net loss of $112.6 million, or $1.10 per share | 2026-11-03 |
| Quarterly report · Q2 2026 BEAM THERAPEUTICS INC. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Marketable Securities: $1,152.9 million (c | 2026-08-04 |
| Results announced · Q3 2026 BEAM THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $1.2 billion in cash, cash equivalents and marketable securiti | 2026-08-04 |
| Shareholder vote results · Q2 2026 BEAM THERAPEUTICS INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 3, 2026 • Total votes cast across all proposals: approx | 2026-06-08 |
| Quarterly report · Q1 2026 BEAM THERAPEUTICS INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net loss Q1 2026: $94.3 million (vs. $108.3 million Q1 2025) • Loss per share: $0.9 | 2026-05-07 |
| Results announced · Q2 2026 BEAM THERAPEUTICS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $1.2 billion in cash, cash equivalents and marketable securities as of | 2026-05-07 |
| Proxy statement · Q2 2026 BEAM THERAPEUTICS INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class III directors—John Evans, John | 2026-04-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| Standby license agreement with Japanese university and Bio Palette established Beam Therapeutics signed a Standby License Agreement with Japanese university Kobe University and Bio Palette Co., Ltd., effective February 9, 2026. This agreement provides Beam with crucial | 2026-02-12 |
| Extended operating runway into 2029; FDA alignment on accelerated approval pathway Beam Therapeutics announced strategic progress on its genetic medicine pipeline. Key highlights: (1) BEAM-302 for alpha-1 antitrypsin deficiency reached FDA alignment on an accelerated appro | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Beam Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.